Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acrivon Therapeutics, Inc.ACRV · Entity 573 | Chief Legal Officer | October 05, 2026 | October 07, 2026 |
| Butterfly Network, Inc.BFLY · Entity 4467 | General Counsel & Corp Sec | March 22, 2022 | March 24, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acrivon Therapeutics, Inc.
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 81,715 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Sale · Disposed 294 · Balance 81,715 F1: Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F2: The price reported in Column 4 above reflects the weighted average price of 337 shares sold by a broker on October 5, 2026, to satisfy the payment of withholding tax liability of a group of employees of the Issuer, including the reporting person. The proceeds of all such sales were allocated to the employees, including the reporting person, on a pro rata basis. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
F2: The price reported in Column 4 above reflects the weighted average price of 337 shares sold by a broker on October 5, 2026, to satisfy the payment of withholding tax liability of a group of employees of the Issuer, including the reporting person. The proceeds of all such sales were allocated to the employees, including the reporting person, on a pro rata basis.
Butterfly Network, Inc.
Report date March 22, 2022 · Filed March 24, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 383,512 |
Reported balance
After 2022-03-22 transaction · row 1
1 source rowRow 1 · 2022-03-22 · Grant · Acquired 54,789 · Balance 383,512 F1: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 33% on March 22, 2023 with the remainder vesting in eight equal quarterly installments thereafter, subject to Ms. Miller's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 33% on March 22, 2023 with the remainder vesting in eight equal quarterly installments thereafter, subject to Ms. Miller's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 7, 2026 21:02 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | SaleCommon Stock | 294 | $1.99 | $585.06 |
DisclosureSEC source: 0000905148-26-004399 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,715 F1 · kind: Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. F2 · price: The price reported in Column 4 above reflects the weighted average price of 337 shares sold by a broker on October 5, 2026, to satisfy the payment of withholding tax liability of a group of employees of the Issuer, including the reporting person. The proceeds of all such sales were allocated to the employees, including the reporting person, on a pro rata basis. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 20:09 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | SaleCommon Stock | 185 | $2.01 | $371.85 |
DisclosureSEC source: 0000905148-26-003839 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,009 F1 · kind: Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| July 21, 2026 Filed Jul 23, 2026 20:28 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | SaleCommon Stock | 573 | $1.76 | $1,008.48 |
DisclosureSEC source: 0000905148-26-003334 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,194 F1 · kind: Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:30 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantCommon Stock | 49,830 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-002553 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,767 F1 · kind: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:11 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 184 | $1.92 | $353.28 |
DisclosureSEC source: 0000905148-26-002501 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,937 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| April 17, 2026 Filed Apr 21, 2026 21:05 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 558 | $1.78 | $993.24 |
DisclosureSEC source: 0000905148-26-001768 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,121 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:19 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 129,760 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0000905148-26-001119 · form4.xml · derivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,760 Underlying: Common Stock · 129,760 shares Expires 2036-02-29 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 21:12 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 217 | $1.63 | $353.71 |
DisclosureSEC source: 0000905148-26-000937 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,679 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| January 17, 2026 Filed Jan 21, 2026 21:02 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 659 | $1.98 | $1,304.82 |
DisclosureSEC source: 0000905148-26-000281 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,896 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 21:32 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 184 | $2.24 | $412.16 |
DisclosureSEC source: 0000905148-25-004130 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,555 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| October 17, 2025 Filed Oct 21, 2025 20:06 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 558 | $1.81 | $1,009.98 |
DisclosureSEC source: 0000905148-25-003637 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,739 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:26 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 284 | $1.81 | $514.04 |
DisclosureSEC source: 0000905148-25-003506 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,297 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| August 14, 2025 Filed Aug 18, 2025 21:18 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 184 | $1.39 | $255.76 |
DisclosureSEC source: 0000905148-25-003042 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,581 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 20:28 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 558 | $1.32 | $736.56 |
DisclosureSEC source: 0000905148-25-002493 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,765 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:20 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 184 | $1.14 | $209.76 |
DisclosureSEC source: 0000905148-25-001823 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,323 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| April 17, 2025 Filed Apr 18, 2025 19:51 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 558 | $1.81 | $1,009.98 |
DisclosureSEC source: 0000905148-25-001257 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,507 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:32 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 15,616 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0000905148-25-001076 · form4.xml · derivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,616 Underlying: Common Stock · 15,616 shares Expires 2035-03-31 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on April 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 22:31 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 93,693 | $0.00 Strike: $5.31 | $0.00 |
DisclosureSEC source: 0000905148-25-000840 · form4.xml · derivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,693 Underlying: Common Stock · 93,693 shares Expires 2035-02-28 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 21:59 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 217 | $5.42 | $1,176.14 |
DisclosureSEC source: 0000905148-25-000729 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,065 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| January 17, 2025 Filed Jan 22, 2025 21:15 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 659 | $5.78 | $3,809.02 |
DisclosureSEC source: 0000905148-25-000168 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,282 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| November 14, 2024 Filed Nov 18, 2024 21:31 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 184 | $7.92 | $1,457.28 |
DisclosureSEC source: 0000905148-24-003227 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,941 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| October 17, 2024 Filed Oct 21, 2024 20:22 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 558 | $7.87 | $4,391.46 |
DisclosureSEC source: 0000905148-24-002773 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,125 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 22:49 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 284 | $6.98 | $1,982.32 |
DisclosureSEC source: 0000905148-24-002637 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,683 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| August 14, 2024 Filed Aug 16, 2024 20:52 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 184 | $7.02 | $1,291.68 |
DisclosureSEC source: 0000905148-24-002282 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,967 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| July 17, 2024 Filed Jul 19, 2024 20:20 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 558 | $7.69 | $4,291.02 |
DisclosureSEC source: 0001140361-24-033600 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,151 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| May 14, 2024 Filed May 16, 2024 23:03 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 184 | $8.36 | $1,538.24 |
DisclosureSEC source: 0000905148-24-001493 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,709 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| April 17, 2024 Filed Apr 19, 2024 20:10 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 558 | $10.34 | $5,769.72 |
DisclosureSEC source: 0000905148-24-001186 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,893 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| March 01, 2024 Filed Nov 27, 2024 23:11 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 67,567 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0000905148-24-003295 · form4.xml · derivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,567 Underlying: Common Stock · 67,567 shares Expires 2034-02-28 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2025, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:14 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 217 | $3.40 | $737.80 |
DisclosureSEC source: 0000905148-24-000765 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,451 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| January 17, 2024 Filed Jan 19, 2024 21:24 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 652 | $4.35 | $2,836.20 |
DisclosureSEC source: 0000905148-24-000240 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,668 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| November 14, 2023 Filed Nov 17, 2023 00:43 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 735 | $5.08 | $3,733.80 |
DisclosureSEC source: 0000905148-23-001477 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,320 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| October 17, 2023 Filed Oct 19, 2023 23:45 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 2,232 | $5.48 | $12,231.36 |
DisclosureSEC source: 0000905148-23-001156 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,055 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| September 26, 2023 Filed Sep 28, 2023 23:17 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 11,576 | $0.00 Strike: $8.95 | $0.00 |
DisclosureSEC source: 0000905148-23-001029 · form4.xml · derivative · entry 2 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,576 Underlying: Common Stock · 11,576 shares Expires 2033-09-25 F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on October 1, 2024, and the remaining shares subject to the option shall vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| September 26, 2023 Filed Sep 28, 2023 23:17 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantCommon Stock | 3,858 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-23-001029 · form4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,287 F1 · kind: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, twenty-five percent (25%) shall vest on October 1, 2024, and the remaining RSUs shall vest in three substantially equal annual installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| March 22, 2022 Filed Mar 24, 2022 21:12 UTC | Butterfly Network, Inc. BFLY · Entity 4467 | GrantClass A Common Stock | 54,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-002943 · primarydocument.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,512 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 33% on March 22, 2023 with the remainder vesting in eight equal quarterly installments thereafter, subject to Ms. Miller's continued service through the applicable vesting date. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:59 UTC | Butterfly Network, Inc. BFLY · Entity 4467 | GrantClass A Common Stock | 189,655 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-031597 · tm228660d4_4.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,723 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 33% on March 4, 2023 with the remainder vesting in eight equal quarterly installments thereafter, subject to Ms. Miller's continued service through the applicable vesting date. Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 22:21 UTC | Butterfly Network, Inc. BFLY · Entity 4467 | SaleCommon Stock | 16,677 | $5.95 | $99,253.17 |
DisclosureSEC source: 0001562180-22-001584 · primarydocument.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,068 F1 · kind: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") that were granted on February 11, 2021 pursuant to a "sell to cover" provision included in the RSU Agreement. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $5.75 to $6.05 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 02:04 UTC | Butterfly Network, Inc. BFLY · Entity 4467 | GrantStock Option (right to buy) · Derivative | 259,575 | Not disclosed Strike: $9.40 | Not disclosed |
DisclosureSEC source: 0001104659-21-024563 · tm216719-20_4seq1.xml · derivative · entry 1 Miller Mary · CIK 0001841088 · GC and CS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,575 Underlying: Class A Common Stock · 259,575 shares Expires 2030-12-17 F2 · price: In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of November 19, 2020, by and among Longview Acquisition Corp. ("Longview"), Clay Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Longview ("Merger Sub"), and Butterfly Network, Inc., a Delaware corporation ("Butterfly"), pursuant to which Merger Sub merged with and into Butterfly, with Butterfly surviving as a wholly-owned subsidiary of Longview (which changed its name to "Butterfly Network, Inc.", the "Issuer"), this stock option was received in exchange for a stock option to acquire 250,000 shares of Butterfly common stock for $9.75 per share. F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on December 31, 2021, with the remainder vesting in 36 equal monthly installments thereafter, subject to Ms. Miller's continued service through the applicable vesting date. Read SEC document |
| February 12, 2021 Filed Feb 25, 2021 21:05 UTC Amendment | Butterfly Network, Inc. BFLY · Entity 4467 | GrantStock Option (right to buy) · Derivative | 259,575 | Not disclosed Strike: $9.40 | Not disclosed |
DisclosureSEC source: 0001104659-21-028226 · tm217907d1_4a.xml · derivative · entry 2 Miller Mary · CIK 0001841088 · GC and CS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,575 Underlying: Class A Common Stock · 259,575 shares Expires 2030-12-17 F4 · price: Received in connection with the Merger in exchange for a stock option to acquire 250,000 shares of Butterfly common stock for $9.75 per share. F3 · derivative.exercise_date: The shares underlying this option vest as to 25% on December 31, 2021, with the remainder vesting in 36 equal monthly installments thereafter, subject to Ms. Miller's continued service through the applicable vesting date. Read SEC document |
| February 12, 2021 Filed Feb 25, 2021 21:05 UTC Amendment | Butterfly Network, Inc. BFLY · Entity 4467 | GrantClass A Common Stock | 155,745 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-028226 · tm217907d1_4a.xml · nonDerivative · entry 1 Miller Mary · CIK 0001841088 · GC and CS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,745 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over four years beginning on February 11, 2022, subject to Ms. Miller's continued service through the applicable vesting date. F2 · price: In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of November 19, 2020, by and among Longview Acquisition Corp. ("Longview"), Clay Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Longview ("Merger Sub"), and Butterfly Network, Inc., a Delaware corporation ("Butterfly"), pursuant to which Merger Sub merged with and into Butterfly (the "Merger"), with Butterfly surviving as a wholly-owned subsidiary of Longview (which changed its name to "Butterfly Network, Inc.", the "Issuer"), these shares were received in exchange for 150,000 RSUs of Butterfly. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.